Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 01, 2022

Benefit of Adjuvant Chemotherapy and Trastuzumab in HER2+ Node-Negative Breast Tumors ≤10 mm

Breast Cancer Research and Treatment


Additional Info

Breast Cancer Research and Treatment
Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study
Breast Cancer Res Treat 2022 Sep 08;[EPub Ahead of Print], CMS Hassing, MK Mejdahl, AV Lænkholm, N Kroman, AS Knoop, THF Tvedskov

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading